Mizuho Securities Reiterates Satsuma Pharmaceuticals (STSA) at Buy, $15 PT, Remains Bullish on STS101's Potential
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $15.00 price target on Satsuma Pharmaceuticals (NASDAQ: STSA), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
